Navigation Links
Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
Date:9/20/2007

pment of new drugs to treat various forms of cancer and gastrointestinal diseases. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including gastrointestinal disorders. One of the Company's lead drug candidates, Atiprimod is presently in a Phase II clinical trial in advanced carcinoid cancer patients, a neuroendocrine tumor, and in a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients. Another anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory acute leukemia, a currently incurable blood cancer. L-Annamycin is currently in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Callisto also has a proprietary drug Guanilib in preclinical development for gastro- intestinal disorders. Callisto has exclusive worldwide licenses from Genzyme Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. More information is available at http://www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty i
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015  Lyric Pharmaceuticals Inc. ... financing round totaling $20.4 million. The financing, co-led by ... includes participation by Aperture Venture Partners. ... by David Wurtman , M.D., M.B.A., President & ... M.D., Chief Medical Officer.  In 2014, Lyric closed a ...
(Date:2/26/2015)... February 26, 2015 Vectorious ... cardiac monitoring system for patients suffering from congestive ... closed a $5 million financing round. Investors in ... owned jointly by Yehuda Zisapel and Prof. ... Gilon, Gur Muntzer and others; and the U.S.-based ...
(Date:2/26/2015)... , Feb. 26, 2015  CSSi, ( ... for the clinical research industry, is pleased to ... as a Project Manager, adding significant value ... Photo - http://photos.prnewswire.com/prnh/20150225/177750 ... a demonstrated ability to successfully lead the navigation ...
Breaking Medicine Technology:Vectorious Medical Technologies Completes $5M Raise 2CSSi's Continued Growth Brings Talented New Hire - Karen Welch Welcomed as Project Manager 2
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... human disease, announced today that Pablo Lapuerta, M.D. has ... for directing clinical development of Lexicon,s drug candidates from ... Lapuerta has 15 years of pharmaceutical industry experience in ...
... March 24, 2011 The pharmaceutical industry has turned to ... pipelines and patent loss. Fixed dose combination (FDC) products not ... products but also the chance to offer payers and patients ... getting to market quickly with an FDC is more myth ...
Cached Medicine Technology:Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer 2Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer 3Successful Strategies and Innovative Practices for Bringing FDC Products to Market 2
(Date:2/26/2015)... Thousands of people in local communities nationwide will ... the Muscular Dystrophy Association during the 2015 MDA Muscle ... will help save and improve the lives of children ... events unite and rally communities to raise funds and ... compromised — including everyday abilities like walking, running, hugging, ...
(Date:2/26/2015)... PartnerTech Inc . has announced it has been ... , The Movers & Makers Awards are presented ... or distribution of tangible products and will be held on ... serves as Georgia’s largest local awards ceremony for manufacturing and ... 300 local industry and business leaders. , “We are ...
(Date:2/26/2015)... The COR HEALTH division of Vets ... NY, to offer customers a full line of Topricin® ... safely and effectively address muscle, joint, and nerve pain. ... Access LLC, Montrose, MI, that is dedicated to providing ... BioMedics is a research and development leader in topical ...
(Date:2/26/2015)... February 26, 2015 In a nested-case control ... the world with a relatively low incidence of liver cancer, ... cancer, according to a new study published February 26 ... , Previous studies have reported this association but most ... liver cancer incidence rate, such as Asia. Katherine A. McGlynn, ...
(Date:2/26/2015)... A Beautiful Smile Dentistry is celebrating ... the following 50 year celebration specials to their patients. ... Sonic Care Diamond Clean or the Braun Oral B ... cost is $2895 for the Invisalign special (this is ... treatment procedures are priced accordingly). The practice is ...
Breaking Medicine News(10 mins):Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 3Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 3Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 2Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 3Health News:A Beautiful Smile Dentistry is Celebrating 50 Years in Practice! 2Health News:A Beautiful Smile Dentistry is Celebrating 50 Years in Practice! 3
... THURSDAY, Dec. 16 (HealthDay News) -- U.S. scientists have unraveled ... cancer in children. Gene sequencing reveals that this tumor, ... adult tumors. The discovery that MB has five to ... attempts to understand what triggers the cancer and which treatment ...
... the Johns Hopkins Kimmel Cancer Center have deciphered the genetic ... a leading killer of children with cancer. The genetic ... pediatric cancer genome and is published online in the December ... findings show that children with medulloblastoma have five- to tenfold ...
... , , , , ... AUDIO: People with a known risk for Alzheimers disease seem to develop ... Click here for more information. , , , ... , , , , , , ...
... The American Heart Association has recognized UC Irvine Healthcare,s ... patients. The Get With The Guidelines Heart Failure ... achieved at least 85 percent compliance for one year with ... medical center,s compliance rate was 96 percent. The "Plus" designation ...
... HealthDay Reporter , THURSDAY, Dec. 16 (HealthDay News) -- A ... the latest legal challenge to the constitutionality of a key ... nearly all Americans must carry health insurance or face a ... sided with that state,s attorney general, who contended that the ...
... radiofrequency ablation (RFA) is a safe and effective therapy ... high repeatability of RFA is advantageous in controlling recurrences ... 10-year retrospective study are available in the January 2011 ... Wiley-Blackwell on behalf of the American Association for the ...
Cached Medicine News:Health News:Gene Research Brings Insight Into Deadly Childhood Brain Tumor 2Health News:Genome code cracked for most common form of pediatric brain cancer 2Health News:Genome code cracked for most common form of pediatric brain cancer 3Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 2Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 3Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 4Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 5Health News:UC Irvine Medical Center recognized for heart failure program 2Health News:Court Fight Over Health-Care Reform Shifts to Florida 2Health News:Court Fight Over Health-Care Reform Shifts to Florida 3Health News:Court Fight Over Health-Care Reform Shifts to Florida 4Health News:Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation 2
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
Medicine Products: